Page last updated: 2024-12-05

dibenzyl ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dibenzyl ether is a colorless liquid with a sweet, aromatic odor. It is used as a solvent and in the synthesis of other organic compounds. Dibenzyl ether is synthesized by reacting benzyl chloride with sodium hydroxide in the presence of a catalyst. Dibenzyl ether is a relatively unreactive compound, but it can be oxidized to benzophenone. Dibenzyl ether is studied for its potential applications in various fields, including organic synthesis, pharmaceuticals, and materials science. The compound is also used as a model system for studying the properties of ethers. Dibenzyl ether is a relatively safe compound, but it should be handled with care as it can be an irritant to the skin and eyes.'

benzyl ether : A compound of formula PhCH2OR (R =/= H). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

dibenzyl ether : A benzyl ether in which the oxygen atom is connected to two benzyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7657
CHEMBL ID152299
CHEBI ID87411
SCHEMBL ID27380
MeSH IDM0205998

Synonyms (87)

Synonym
BIDD:ER0268
nsc5931
wln: r1o1r
benzyl ether
benzene,1'-[oxybis(methylene)]bis-
benzyl oxide
ba (plasticizer)
103-50-4
plastikator ba
nsc-5931
dibenzyl ether
dibenzylether
nsc 5931
1,1'-(oxybis(methylene))bisbenzene
brn 1911156
ether, dibenzyl
ai3-02269
plasticator ba
benzene, 1,1'-(oxybis(methylene))bis-
hsdb 6030
einecs 203-118-2
fema no. 2371
fema number 2371
ccris 6085
dibenzylether [czech]
ba (van)
benzyl oxide [czech]
benzene, 1,1'-oxybis(methylene-
1,1-(oxybis(methylene))bisbenzene
1,1-oxybismethylene, bis benzene
benzene, 1,1'-[oxybis(methylene)]bis-
ether,dibenzyl
1,1'-[oxybis(methylene)]dibenzene
inchi=1/c14h14o/c1-3-7-13(8-4-1)11-15-12-14-9-5-2-6-10-14/h1-10h,11-12h
NCGC00091363-01
1,1-oxybis methylene, bis benzene
benzyl ether, >=98%, fcc, fg
benzyl ether, 98%
B0418
1-benzyloxymethylbenzene(benzyl ether)
chebi:87411 ,
CHEMBL152299
smr001216521
MLS001050086
phenylmethoxymethylbenzene
A800755
NCGC00091363-02
ec 203-118-2
2o6cno27rj ,
4-06-00-02240 (beilstein handbook reference)
unii-2o6cno27rj
tox21_200903
dtxsid5025819 ,
dtxcid005819
NCGC00258457-01
cas-103-50-4
[(benzyloxy)methyl]benzene
FT-0624653
AKOS015914994
dibenzyl ether [fcc]
dibenzyl ether [fhfi]
tribenoside impurity d [ep impurity]
benzyl ether [mi]
dibenzyl ether [hsdb]
bn2o
mono-benzyl ether
benzylether
SCHEMBL27380
(oxybis(methylene))dibenzene
Q-200956
[(benzyloxy)methyl]benzene #
mfcd00004780
dibenzyl ether, analytical standard
dibenzyl ether, purum, >=98.0% (gc)
tribenoside impurity d, european pharmacopoeia (ep) reference standard
1,1'-[oxybis(methylene)]bisbenzene, 9ci
fema 2371
phenylmethoxy-methyl-benzene
benzyl ether, 8ci
oxybis(methylene)dibenzene
Q11309584
ethyl?benzo[d]thiazole-6-carboxylate
BS-14196
dibenzyl ester
tribenoside impurity d
CS-W010535
?benzyl ether
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzyl etherA compound of formula PhCH2OR (R =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency50.11870.000214.376460.0339AID588532
pregnane X nuclear receptorHomo sapiens (human)Potency35.48130.005428.02631,258.9301AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency1.02040.000229.305416,493.5996AID743075
Nuclear receptor ROR-gammaHomo sapiens (human)Potency26.60320.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (5.88)18.2507
2000's5 (29.41)29.6817
2010's9 (52.94)24.3611
2020's2 (11.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.89 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index78.19 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]